ArticleCureus2025
Cutaneous Lymphoid Hyperplasia: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous lymphoid hyperplasia (CLH) is a localized reactive proliferation of polyclonal lymphoid cells in the skin. The condition can be idiopathic or result from various stimuli, with indolent nodular/papular lesions on exposed body areas. Despite its benign nature, it mimics cutaneous lymphomas both clinically and histologically. We present the case of a 56-year-old male patient who developed multiple erythematous papules and nodules on the forehead, gradually increased in size and number over a period of two months. Routine histological studies revealed dermal lymphocytic infiltrates, multiple lymphoid follicles with germinal centers containing tingible body macrophages. Immunohistochemical staining revealed a mixed population of B and T lymphocytes. The reactive germinal centers retained immunoreactivity for CD10 but did not show co-expression of BCL2. These findings confirmed the diagnosis of CHL. The patient was treated with three sessions of pulsed dye laser (PDL), followed by intralesional steroid and topical tacrolimus, with uneventful recovery after five years of follow-up. We also discuss the etiology, clinical features, diagnosis, and available management modalities for CLH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.